Betta Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jan '22 Jan 1, 2022
Operating Revenue	3,700	3,578	2,827	2,417	2,342	2,206
Other Revenue	31.67	31.67	64.95	39.41	34.18	40.05
Revenue	3,732	3,609	2,892	2,456	2,377	2,246
Revenue Growth (YoY)	21.40%	24.81%	17.74%	3.35%	5.82%	20.08%
Cost of Revenue	784.36	738.66	538.52	404.48	268.69	174.44
Gross Profit	2,947	2,871	2,353	2,052	2,108	2,071
Selling, General & Admin	1,788	1,779	1,363	1,116	1,234	1,141
Research & Development	495.01	510.87	501.9	640.14	699.9	565.95
Other Operating Expenses	50.87	40.88	18.19	10.62	-34.51	15.24
Operating Expenses	2,334	2,330	1,876	1,772	1,901	1,723
Operating Income	613.18	540.45	476.96	279.88	206.96	348.77
Interest Expense	-72.47	-76.14	-45.49	-54.95	-195.8	-15.78
Interest & Investment Income	3.25	4.29	6.78	10.23	10.88	33.35
Currency Exchange Gain (Loss)	-12.62	-12.62	4.14	6.72	9.55	-3.63
Other Non Operating Income (Expenses)	-10.79	-1.19	-6.57	-4.96	-9	-0.84
EBT Excluding Unusual Items	520.56	454.79	435.82	236.92	22.59	361.88
Gain (Loss) on Sale of Investments	14.71	-79.33	-40.97	-13.67	-20.62	1.01
Gain (Loss) on Sale of Assets	0.31	0.38	-0.59	-0.01	88.61	0.07
Asset Writedown	-0.01	-0.01	-28.05	-1.07	-3.01	-0.03
Other Unusual Items	38.1	38.53	27.95	99.9	-	27.01
Pretax Income	573.68	414.36	394.16	322.07	87.57	389.93
Income Tax Expense	151.77	128.15	7.18	-11.54	-37.19	10.37
Earnings From Continuing Operations	421.9	286.21	386.98	333.62	124.76	379.56
Minority Interest in Earnings	19.25	19.12	15.59	14.42	20.66	3.51
Net Income	441.16	305.33	402.57	348.03	145.42	383.07
Net Income to Common	441.16	305.33	402.57	348.03	145.42	383.07
Net Income Growth	9.06%	-24.15%	15.67%	139.33%	-62.04%	-36.83%
Shares Outstanding (Basic)	419	418	419	419	416	416
Shares Outstanding (Diluted)	419	418	419	419	416	416
Shares Change (YoY)	0.57%	-0.26%	0.01%	0.72%	-0.02%	2.32%
EPS (Basic)	1.05	0.73	0.96	0.83	0.35	0.92
EPS (Diluted)	1.05	0.73	0.96	0.83	0.35	0.92
EPS Growth	8.43%	-23.96%	15.66%	137.47%	-62.01%	-38.26%
Free Cash Flow	101.57	294.58	83.58	-181.79	-703.8	-231.75
Free Cash Flow Per Share	0.24	0.70	0.20	-0.43	-1.69	-0.56
Dividend Per Share	0.150	0.150	0.200	0.170	0.070	0.250
Dividend Growth	-25.00%	-25.00%	17.65%	142.86%	-72.00%	-19.36%
Gross Margin	78.98%	79.53%	81.38%	83.53%	88.69%	92.23%
Operating Margin	16.43%	14.97%	16.49%	11.39%	8.71%	15.53%
Profit Margin	11.82%	8.46%	13.92%	14.17%	6.12%	17.06%
Free Cash Flow Margin	2.72%	8.16%	2.89%	-7.40%	-29.61%	-10.32%
EBITDA	1,206	1,088	845.1	578.14	453.58	517.89
EBITDA Margin	32.32%	30.15%	29.22%	23.54%	19.09%	23.06%
D&A For EBITDA	592.88	547.93	368.14	298.26	246.62	169.12
EBIT	613.18	540.45	476.96	279.88	206.96	348.77
EBIT Margin	16.43%	14.97%	16.49%	11.39%	8.71%	15.53%
Effective Tax Rate	26.46%	30.93%	1.82%	-	-	2.66%
Revenue as Reported	3,732	3,609	2,892	2,456	2,377	2,246
Advertising Expenses	-	-	-	-	414.75	459.29

Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.